logo

ETON

Eton Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ETON fundamentals

Eton Pharmaceuticals (ETON) released its earnings on Nov 6, 2025: revenue was 22.50M (YoY +118.45%), beat estimates; EPS was 0.04 (YoY +100.00%), missed estimates.
Revenue / YoY
22.50M
+118.45%
EPS / YoY
0.04
+100.00%
Report date
Nov 6, 2025
ETON Earnings Call Summary for Q3,2025
  • 118% Revenue Surge: Q3 revenue at $22.5M, driven by rare disease treatments.
  • 70% Gross Margin Target: 2025 Q4 guidance with rare disease focus.
  • 5x Market Expansion: INCRELEX label harmonization for 2026 growth.
  • FDA Pipeline Momentum: ET-600 PDUFA in Feb 2026, ET-700 study launch.
EPS
Revenue

Revenue & Expenses

ETON has released its 2025 Q3 earnings report, with revenue of 22.46M, reflecting a YoY change of 117.54%, and net profit of -1.93M, showing a YoY change of -407.34%. The Sankey diagram below clearly presents ETON's revenue sources and cost distribution.

Key Indicators

Eton Pharmaceuticals (ETON) key financial stats and ratios, covering profitability, financial health, and leverage.
Eton Pharmaceuticals (ETON)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Eton Pharmaceuticals (ETON)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Eton Pharmaceuticals (ETON)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Eton Pharmaceuticals (ETON) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Eton Pharmaceuticals (ETON) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield